New hope for lung cancer patients: targeted therapy trial challenges standard chemotherapy
NCT ID NCT06956001
Summary
This study compares a new targeted drug called firmonertinib against standard chemotherapy for people with advanced non-small cell lung cancer who have specific genetic changes (EGFR PACC or L861Q mutations). About 300 participants will be randomly assigned to receive either the daily pill (firmonertinib) or chemotherapy infusions. Researchers want to see which treatment better controls cancer growth and improves quality of life for patients who haven't had previous treatment for their advanced cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ethics Committee of cancer hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shandong Tumor Hospital
RECRUITINGShandong, Jinan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.